Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novare Surgical Systems Inc.

This article was originally published in Start Up

Executive Summary

Novare is taking the basic concept of Fogarty clamps, which reduce vessel trauma and emboli when cross-clamping a diseased blood vessel, and improving on it so that a surgeon can use devices in every procedure.

You may also be interested in...



Navel Maneuver: Single-Port Surgery

Laparoscopic surgeons see Natural Orifice Transluminal Endoscopic Surgery ( NOTES) as next decade's revolution. In the near term, they believe that single-port surgery, which uses the navel the point of entry for all laparoscopic tools, is the next logical step in minimally invasive surgery. It enables surgeons to be even less invasive than current procedures, and patients like invisible scars. We take an early look at the emerging field of single port surgery.

Novare Shifts Gears

Novare Surgical Systems, founded eight years ago to improve upon the Fogarty Clamp and now emerging from a discouraging five-year slump, is finding success--but in an entirely different business. In developing next generation laparoscopic tools, Novare executives believe they’re introducing a paradigm shift.

Novare Shifts Gears

Novare Surgical Systems, founded eight years ago to improve upon the Fogarty Clamp and now emerging from a discouraging five-year slump, is finding success--but in an entirely different business. In developing next generation laparoscopic tools, Novare executives believe they’re introducing a paradigm shift.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037151

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel